Roche has provided an update on its phase III study program comprising four Phase 3 trials evaluating the investigational medicine etrolizumab in people with moderately to severely active ulcerative colitis. These trials are titled HIBISCUS I, HIBISCUS II, HICKORY, and . Roche has reported that in the HIBISCUS I induction…
